Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients
A phase II clinical trial compared standard TNT (mFolfox6 and CRT) with preoperative chemoradiotherapy (CRT) with neoadjuvant chemotherapy (CT) containing mFolfirinox in patients with locally advanced rectal cancer.
Rectum Cancer
DRUG: mFOLFIRINOX|DRUG: mFolfox6
Complete clinical response rate, an absence of clinical, endoscopic or imaging evidence of a rectal tumor during the restaging of a patient with locally advanced rectal cancer after neoadjuvant therapy., 6 months
Toxicity of chemotherapy, Common Terminology Criteria for Adverse Events (CTCAE) v 5, 6 months|complete pathological response rectal cancer, the absence of malignant cells on the specimen of rectal resection in patients who were previously treated with neoadjuvant CRT., 6 months|disease-free survival, Disease-free survival (DFS) will be defined as the time from randomization to recurrence of tumor or death, 3 years|Overall survival, Overall survival will be defined as the time from randomisation to the time of occurrence of the first death regardless to its cause. Patients alive at the time of analysis will be censored at the date of the last follow up., 5 years
This open-label randomized, two-arm phase II trial compared the standard total neoadjuvant approach (TNT) with neoadjuvant CT with mFolfirinox and preoperative CRT in patients with locally advanced rectal cancer.